Recent News

• 01.23.2026 - Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony
• 01.22.2026 - Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile
• 01.20.2026 - Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026
• 01.12.2026 - Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women
• 01.05.2026 - Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates
• 12.22.2025 - Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform

Recent Filings

• 01.05.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.02.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 12.31.2025 - EFFECT Notice of Effectiveness
• 12.30.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 12.30.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 12.30.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 12.30.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 12.30.2025 - 253G2 253G2
• 12.30.2025 - S-3 Registration statement under Securities Act of 1933
• 12.30.2025 - 424B3 Prospectus [Rule 424(b)(3)]